microRNA 4431 (MIR4431)

microRNA 4431 (MIR4431) is an endogenous, small non-coding RNA molecule (about 18–25 nucleotides) that plays a role in regulating gene expression by binding to complementary sequences in messenger RNA (mRNA), typically leading to mRNA degradation or the inhibition of translation[1][2][3]. Unlike protein-coding therapeutic targets such as receptors, enzymes, or ion channels, MIR4431 itself is not commonly considered a direct drug target or established therapeutic target in current biomedical literature. Although microRNAs as a class are broadly implicated in diverse biological processes—such as cell cycle regulation, apoptosis, immune response, and cancer progression—there is little to no evidence in the recent literature or curated target databases that asserts MIR4431 is an established therapeutic target, a biomarker for disease, a point of drug interaction, or specifically linked to notable clinical safety concerns[1][2][3]. Searches of major resources reveal minimal or no published experimental data specific to MIR4431 in disease roles or clinical applications, and there are no known drugs targeting MIR4431 directly. This suggests either missing information regarding MIR4431 or that it may have been mistakenly designated as a therapeutic target. Most authoritative studies and miRNA analyses do not list MIR4431 among important regulatory, diagnostic, or therapeutic molecules in cancer or other major diseases[1][2][3]. If you require structured information about major microRNAs used in clinical diagnostics, research contexts, or drug development, consider referring to better-characterized miRNAs such as miR-21, miR-34a, or those included in standard miRNA panels for cancer classification[1][2].

Other names

hsa-mir-4431MIR4431microRNA 4431